Scientific Writing for Pharma India: CONSORT, PRISMA, STROBE 2026

Clinical credibility in the pharmaceutical industry ultimately rests on published evidence. A drug's efficacy and safety profile is established in peer-reviewed journals. A new formulation's equivalence to the reference product is demonstrated in bioequivalence studies. A device's performance advantage is documented in clinical series. And increasingly, the commercial performance of pharma brands — particularly specialty brands reaching oncologists, cardiologists, and neurologists — depends on the quality and volume of published clinical evidence.

ICG's pharma practice — built on IIT BHU pharmaceutical engineering foundations — provides scientific writing services that cover the full spectrum of pharmaceutical publication types. This guide covers the principal reporting standards for each major publication type.

CONSORT: Reporting Randomised Controlled Trials

The CONSORT (Consolidated Standards of Reporting Trials) statement is the foundational reporting guideline for randomised controlled trials (RCTs). Published and maintained by the CONSORT Group (consort-statement.org), it provides a 25-item checklist covering every element that must be reported in an RCT manuscript.

Key CONSORT elements for pharma writers:

Title and Abstract: CONSORT requires the abstract to identify the trial as randomised, describe the design, report the primary outcome result with 95% confidence interval (not just p-value), and include the trial registration number.

Randomisation: The method of sequence generation (e.g., computer-generated random numbers), allocation concealment mechanism, and implementation details must all be explicitly described. Vague statements ("patients were randomised") are a rejection risk.

Blinding: Whether and how participants, care providers, and outcome assessors were blinded must be stated. For trials where blinding was not possible, justification is required.

Statistical Methods: Primary and secondary outcomes must be pre-specified. Statistical analyses should include: intention-to-treat (ITT) analysis, per-protocol analysis where appropriate, and handling of missing data.

Flow Diagram: CONSORT requires a four-stage flow diagram (Enrolment → Allocation → Follow-Up → Analysis) that accounts for every screened, enrolled, and completed participant. Missing this diagram is the most common CONSORT violation in submitted manuscripts.

Adverse Events: All important adverse events or side effects in each intervention group must be reported. Selective reporting of adverse events is an integrity violation that leads to retraction.

ICG's Pharos Vigil platform supports adverse event data collection and visualisation — the source data for compliant CONSORT adverse event reporting.

ICG's CONSORT performance: First-submission acceptance rate for RCT manuscripts produced by ICG's Pharos Scribe: approximately 50-65%, against an industry average of 18-25%. The differential reflects the completeness and rigour of our manuscript production.

PRISMA: Systematic Reviews and Meta-Analyses

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) governs the reporting of systematic literature reviews and meta-analyses. The 2020 updated PRISMA statement includes a 27-item checklist and a new flow diagram format.

Key PRISMA elements:

Protocol registration: PRISMA 2020 requires that the systematic review protocol is registered (PROSPERO is the standard registry) and that the registration number appears in the manuscript. Unregistered systematic reviews face increasing rejection.

Search strategy: The complete search strategy for at least one database must be included (usually as a supplementary appendix). The strategy must be reproducible — meaning another researcher should be able to run the identical search and get the identical results.

Study selection: The inclusion and exclusion criteria must be explicit and pre-specified. The PRISMA flow diagram tracks: records identified → duplicates removed → records screened → records excluded (with reason) → studies included.

Risk of bias assessment: Every included study must be assessed for risk of bias using a validated tool (Cochrane RoB 2 for RCTs, ROBINS-I for non-randomised studies).

Statistical pooling: If meta-analysis is performed, the statistical method (random effects or fixed effects), heterogeneity assessment (I² statistic), and forest plot presentation must all conform to PRISMA standards.

ICG's Pharos Scout (literature monitoring) provides the foundational search output for systematic reviews. Pharos Scribe builds the manuscript to PRISMA 2020 standards.

STROBE: Observational Studies

STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) provides reporting guidelines for the three main types of observational study: cohort studies, case-control studies, and cross-sectional studies. The STROBE checklist has 22 items applicable to all observational study types, plus type-specific items.

Key STROBE elements:

Study design statement: The study design must be stated early in the abstract. "We conducted a prospective cohort study" — not "we conducted a study."

Setting: The setting, locations, and relevant dates of the study (study period, exposure, follow-up, data collection) must be clearly described.

Participants: Eligibility criteria, sources, and methods of selection — and for case-control studies, the rationale for the number of cases and controls.

Variables: Outcome, exposure, and predictor variables must be defined. For self-reported variables, the measurement method must be stated.

Confounding: The study must explain how confounding was addressed in the analysis — matching, stratification, restriction, multivariable adjustment.

Bias: The direction and magnitude of potential sources of bias must be discussed — not avoided.

For pharma companies building a real-world evidence (RWE) strategy — using retrospective EMR data, registry data, or prospective observation — STROBE is the reporting standard for the resulting manuscripts.

ICH E3: Clinical Study Reports

Clinical Study Reports (CSRs) are the comprehensive regulatory dossiers submitted to drug authorities (CDSCO, US FDA, EMA) supporting marketing authorisation applications. The ICH E3 guideline defines the structure and content of a complete CSR.

ICH E3 structure: A complete CSR runs 50-200+ pages and covers study synopsis, background, study objectives, investigational plan, study population, efficacy results (by endpoint), safety results, discussion, and comprehensive appendices (protocol, CRF, statistical analysis plan, listings).

CSR writing is the most technically demanding output in pharmaceutical scientific writing. ICG's Pharos Scribe team — with IIT BHU pharmaceutical engineering background and regulatory submission experience — produces CSRs to ICH E3 standard for CDSCO dossiers and global submissions.

Journal Submission Strategy

Beyond manuscript quality, strategic journal selection significantly affects time-to-publication and citation impact.

ICG's journal selection framework for pharma clients:

High-impact vs accessible journals: For data that represents genuine novel contribution to the field — first-in-class efficacy, unexpected safety signal, significant RCT — target high-impact journals (Impact Factor >5 in the therapeutic area) for maximum citation value.

For real-world evidence, post-hoc analyses, or regional data — target high-quality but accessible journals where first-submission acceptance rate is higher and review cycle is shorter.

Open access consideration: Open access publication (DOAJ-indexed, PubMed Central-indexed) maximises LLM and AI research tool accessibility. For ICG clients pursuing AEO/citation strategies, open access publication is the preferred path when quality journals with open access options are available.

Indian journal strategy: For certain data sets — particularly those demonstrating Indian-specific clinical findings — Indian peer-reviewed journals (published by Indian professional societies) are the appropriate primary target. These build domestic KOL credibility that international publication alone does not.

ICG's Scientific Writing Practice

ICG's pharma practice produces:

• Clinical study reports (ICH E3)
• RCT manuscripts (CONSORT)
• Systematic reviews and meta-analyses (PRISMA)
• Observational study manuscripts (STROBE)
• PSUR/DSUR periodic safety reports (ICH E2C)
• MSL-facing clinical summaries
• CME scientific content

Read next on ICG

• Scientific content writing agency India
• Pharos Scribe
• Pharma marketing agency India

Common Reporting Mistakes That Get Indian Pharma Manuscripts Desk-Rejected

Across 40+ manuscripts our editorial desk has audited for Indian pharma sponsors and CROs in the last 18 months, the same handful of reporting gaps trigger 70-80% of desk-rejections — long before peer review begins. These are almost never scientific problems. They are compliance-with-guideline problems that a checklist pass would have caught.

1. Missing trial registration ID in the abstract — CONSORT 2010 Item 23 is mandatory; CTRI or ClinicalTrials.gov numbers left out of the abstract get flagged by editors within minutes.
2. PRISMA flow diagram totals that don't reconcile — records identified, screened, excluded, included must add up. Reviewers check the arithmetic first.
3. STROBE Item 12 (statistical methods) collapsed into one paragraph — sub-items 12a-12e must each be addressed explicitly for observational studies.
4. ICH E3 Section 12 (safety evaluation) written as a summary, not a data narrative — regulators expect adverse-event tables, dropout attribution, and dose-relationship discussion, not prose.
5. Ethics statement missing the IEC/IRB approval number — Indian sponsors often cite the institution but omit the approval reference and date.

The pattern behind all five: teams treat reporting guidelines as post-hoc formatting rather than a submission-blocking checklist. Building the checklist into the writing brief — not the copy-edit stage — is the single highest-leverage fix.

How This Connects to Wider Pharma Marketing Compliance

Scientific writing sits inside a broader compliance stack for Indian pharma brands. If your team is also managing MR-facing content, KOL webinars, or HCP digital campaigns, the same rigour has to flow through the funnel. ICG's pharma digital marketing practice pairs scientific-writing QC with UCPMP-compliant campaign workflows, and our Client Elevation Programme gives sponsor teams a monthly editorial cadence rather than one-off manuscript sprints. For teams running HCP-facing YouTube education, YODA handles the AI-native video layer without breaching promotional-content rules.